7 completed, 3 recruiting, 2 active not recruiting, 2 withdrawn. 17 Phase 2, 9 Phase 1, 1 Phase 3.
Follow Genetic Therapy: new trials by email Literature Review of Genetic Therapy trials Research Report on Genetic Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease gene therapy - GBA1 Parkinson Disease | Phase 1 / Phase 2 | Withdrawn | Capsida Biotherapeutics, Inc. | 2025-08-18 | 2026-06-22 | |
| A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy gene therapy - Developmental and Epileptic Encephalopathy | Phase 1 / Phase 2 | Terminated | Capsida Biotherapeutics, Inc. | 1 | 2025-07-03 | 2026-06-10 |
| Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure AB-1002 - Congestive Heart Failure | Phase 2 | Active not recruiting | AskBio Inc | 150 | 2023-10-20 | 2025-12-03 |
| An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3 | Phase 2 / Phase 3 | Withdrawn | AVROBIO | 2023-10-01 | 2023-08-09 | |
| Gene Therapy for IGHMBP2-Related Diseases Gene Therapy - SMARD1, CMT2S | Phase 1 / Phase 2 | Enrolling by invitation | Megan Waldrop | 10 | 2021-11-04 | 2026-10-30 |
| Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID Gene therapy - Severe Combined Immunodeficiency Due to RAG1 Deficiency | Phase 1 / Phase 2 | Suspended | Videja B.V. | 10 | 2021-07-23 | 2026-07-16 |
| PDE6A Gene Therapy for Retinitis Pigmentosa subretinal injection of rAAV.hPDE6A - Retinitis Pigmentosa | Phase 1 / Phase 2 | Active not recruiting | STZ eyetrial | 9 | 2019-09-24 | 2024-04-18 |
| Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery HSV-Tk, Valacyclovir, Bicalutamide - High-risk Prostate Cancer, Prostate Cancer | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 60 | 2018-08-02 | 2021-04-06 |
| HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM ADV/HSV-tk (gene therapy) - Glioblastoma, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 62 | 2018-02-28 | 2026-03-30 |
| HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM ADV/HSV-tk (gene therapy) - Glioblastoma Multiforme, Astrocytoma, Grade III | Phase 1 / Phase 2 | Recruiting | David Baskin MD | 62 | 2017-12-11 | 2026-03-30 |
| A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 BIIB111 - Choroideremia | Phase 2 | Completed | Biogen | 66 | 2017-11-29 | 2024-02-23 |
| A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC gene therapy - Aromatic L-amino Acid Decarboxylase (AADC) Deficiency | Phase 1 / Phase 2 | Completed | National Taiwan University Hospital | 10 | 2014-10-22 | 2023-02-10 |
| Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline) - Painful Diabetic Neuropathies | Phase 2 | Completed | Helixmith Co., Ltd. | 104 | 2012-08-01 | 2025-10-06 |
| ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID Gene Therapy, Busulfan - Immunologic Deficiency Syndromes | Phase 2 | Completed | Fondazione Telethon | 12 | 2002-10-02 | 2024-01-29 |
| Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy - Hepatocellular Carcinoma, Liver Transplantation | Phase 2 | Completed | Beijing Chao Yang Hospital | 40 | 2000-09-01 | 2006-03-09 |
| Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer gene therapy, interleukin-2 gene, methotrexate - Head and Neck Cancer | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 2000-06-01 | 2013-05-30 | |
| Gene Therapy for ADA-SCID gene transduced PBL and/or gene transduced HSC - Severe Combined Immunodeficiency Syndrome | Phase 1 / Phase 2 | Completed | IRCCS San Raffaele | 8 | 1992-03-01 | 2008-01-24 |
Astrocytoma (2) · Glioblastoma (2) · Aromatic amino acid decarboxylase deficiency (1) · Carcinoma, Hepatocellular (1) · Choroideremia (1) · Diabetic Neuropathies (1) · Gaucher Disease (1) · Head and Neck Neoplasms (1) · Heart Failure (1) · Hypesthesia (1) · Immunologic Deficiency Syndromes (1) · Neuralgia (1) · Paresthesia (1) · Parkinson Disease (1) · Prostatic Neoplasms (1)
Capsida Biotherapeutics, Inc. (2) · The Methodist Hospital Research Institute (2) · AVROBIO (1) · AskBio Inc (1) · Beijing Chao Yang Hospital (1) · Biogen (1) · David Baskin MD (1) · Fondazione Telethon (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Helixmith Co., Ltd. (1) · IRCCS San Raffaele (1) · Megan Waldrop (1) · National Taiwan University Hospital (1) · STZ eyetrial (1) · Videja B.V. (1)
United States (10) · Germany (3) · Netherlands (2) · Poland (2) · Spain (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · France (1) · Hungary (1) · Israel (1) · Italy (1) · Romania (1)
Melanie Brandabur, MD (2) · Arjan C Lankester, Prof.dr. (1) · Bordignon Claudio, MD (1) · David S Baskin, MD (1) · David S. Baskin, MD (1) · Ding Ma, M.D. (1) · Dominik Fischer, Prof. (1) · E. Brian Butler, MD (1) · Fondazione Telethon (1) · Jack Kessler, MD (1) · Megan Waldrop, MD (1) · Milena Veselinovic, MD, PhD (1) · Ning Li, B.D (1) · Thomas V. McCaffrey, MD, PhD (1)
PMID 18218852, PMID 19179314, PMID 19633200, PMID 19652199, PMID 22184407, PMID 26000320, PMID 27129325, PMID 28319446, PMID 30169182, PMID 30194931, PMID 32322605, PMID 34763085, PMID 38355973, PMID 38970425, PMID 39878701
2017 (1), 2019 (1), 2023 (1)